A review of traditional Chinese medicine for treatment of glioblastoma

Jinjing Wang¹, Fanghua Qi², Zhixue Wang², Zhikun Zhang¹, Ni Pan¹, Lei Huai¹, Shuyu Qu¹, Lin Zhao²,*

¹Shandong University of Traditional Chinese Medicine, Ji’nan, China; ²Department of Traditional Chinese Medicine, Shandong Provincial Hospital affiliated to Shandong University, Ji’nan, China.

Summary

Glioblastoma (GBM) is the most common primary malignant intracranial tumor. Due to its high morbidity, high mortality, high recurrence rate, and low cure rate, it has brought great difficulty for treatment. Although the current treatment is multimodal, including surgical resection, radiotherapy, and chemotherapy, it does not significantly improve survival time. The dismal prognosis and inevitable recurrence as well as resistance to chemoradiotherapy may be related to its highly cellular heterogeneity and multiple subclonal populations. Traditional Chinese medicine has its own unique advantages in the prevention and treatment of it. A comprehensive literature search of anti-glioblastoma active ingredients and derivatives from traditional Chinese medicine was carried out in literature published in PubMed, Scopus, Web of Science Cochrane library, CNKI, Wanfang, and VIP database. Hence, this article systematically reviews experimental research progress of some traditional Chinese medicine in treatment of glioblastoma from two aspects: strengthening vital qi and eliminating pathogenic qi. Among, strengthening vital qi medicine includes panax ginseng, licorice, lycium barbarum, angelica sinensis; eliminating pathogenic medicine includes salvia miltiorrhiza bunge, scutellaria baicalensis, coptis rhizoma, thunder god vine, and sophora flavescens. We found that the same active ingredient can act on different signaling pathways, such as ginsenoside Rg3 inhibited proliferation and induced apoptosis via the AKT, MEK signal pathway. Hence, this multi-target, multi-level pathway may bring on a new dawn for the treatment of glioblastoma.

Keywords: Glioblastoma (GBM), traditional Chinese medicines (TCMs), active ingredients, migration and invasion, autophagy, signal pathway

1. Introduction

Gliomas, which arise from glial or precursor cells, are the most common primary intracranial tumors. Gliomas includes diffuse astrocytic, oligodendrogial tumor, glioblastoma, ependymal tumor and so on (1,2). According to the World Health Organization (WHO) classification system, gliomas are classified into WHO grade I-IV. 

Among these, WHO grade I and WHO grade II belong to low grade gliomas, WHO grade III and WHO grade IV belong to high grade gliomas. The higher the level, the higher the degree of malignancy, and the worse the prognosis. Clearly, glioblastoma (GBM), belonging to WHO grade IV, is the most frequent as well as malignant glioma in astrocytoma. In 2016, WHO according to histology combined with molecular features reclassified central nervous system (CNS) tumors, and glioblastomas were divided into glioblastoma, IDH-wildtype, glioblastoma, IDH-mutant, as well as glioblastoma, not otherwise specified (NOS) (2). Among glioblastomas, IDH-wildtype is mostly known as primary or do novo glioblastoma, accounting for about 90% of patients, and it is more common in elderly people over 60 years old, with poor prognosis. However, glioblastoma, IDH-
The traditional Chinese medicines against glioblastoma, is mostly evolved from low grade astrocytoma and it is more common in young people, with better prognosis, only accounting for about 10% of patients in clinic (3).

Glioblastoma has characteristics of three high and one low, namely high morbidity, high mortality, high recurrence rate, low cure rate, so the prognosis of it is very poor. According to CBTRUS statistical report in the United States in 2007-2011, it accounts for 15.4% of the primary brain tumors and 45.6% of the primary malignant brain tumors (1). The morbidity of glioblastoma is about 3.19 per 100,000 population in malignant tumors and 4.39 per 100,000 population in primary brain tumors (4). The incidence of glioblastoma increases with age mostly focused on 75 to 84 years, and the 5-year survival rate of patients is about 5% (1). The conventional treatment of glioblastoma is surgical resection as far as possible, followed by radiotherapy and adjuvant chemotherapy, however, its median survival is only 15 months without significant improvement (4, 5).

As tumor cells of glioblastoma can infiltrate into normal brain tissue, the majority of glioblastomas invariably recur despite initial treatment (6). The most advanced multimodal treatment can effectively prolong survival, however, the operation can easily cause side effects such as cerebral hemorrhage and cerebral edema, radiotherapy can cause radiation brain damage and chemotherapy can cause severe bone marrow suppression, nausea, vomiting and so on, which seriously affects patients' quality of life. The dismal prognosis and inevitable recurrence as well as resistance to chemoradiation in glioblastoma may be attributed to its cellular heterogeneity and multiple subclonal populations (4). In addition, according to genomic profiling, the four glioblastoma subtypes have been defined, namely classical, mesenchymal, neural, and pro-neural and different subtypes may require different treatments (7). Hence, in order to improve the survival rate of GBM patients, it is necessary to adopt novel personalized treatment programs such as targeted therapy, immunotherapy, traditional Chinese medicine therapy and other ways. Although there are three signaling pathways (RTK/RAS/PI3K, P53 and RB signaling) in GBM, the efficacy of related inhibitors is limited in targeted therapy of clinical trials (8). Similarly, a part of the tumor vaccines have been terminated in clinical trials of GBM immunotherapy because the effect is not obvious (9). PD-1/PD-L1 inhibitors and CTLA-4 inhibitors have been proved to effectively inhibit other tumors such as melanoma, but the role of anti-GBM is still clearly illustrated (9). Therefore, immunotherapy and targeted therapy have broad prospects in the clinical application of glioblastoma. Of course, so is traditional Chinese medicine therapy.

Traditional Chinese Medicine (TCM) has a unique and integrative theoretical system. It is a summary of the Chinese people's experience in their struggle against diseases, with a history of thousands of years. The holistic concept and syndrome differentiation are the dominant idea in clinical practice. TCM, as an important part of complementary and alternative medicine, plays an important role in various diseases, whether used alone or in combination with western therapy. As we all known, in October 2015, Chinese scientist Tu Youyou was honored with the Nobel Prize in Physiology or Medicine because she discovered artemisinin, an extract derived from Artemisia annua, which can significantly and effectively treat malaria results while saving millions of lives (10). Of course, TCM has its own unique advantages in the prevention and treatment of tumors. Overall, TCM can prevent the formation of tumors, increase efficiency and reduce toxicity, reduce tumor recurrence and metastasis, prolong survival time and improve patients' quality of life (11). Without doubt, no matter a single or formulations of traditional Chinese herbs, TCM has also made great achievements in cancer. Such as, PHY906 (YIV-906), a mixture of four herbs (Astragalus, Licorice, Peony, Jujube), which was developed by Yale university professor Yungchi Cheng, and combined with chemotherapy and radiotherapy has significant effects on clinical trials of colorectal cancer, liver cancer and pancreatic cancer. In addition, Vincristine is a naturally alkaloid extracted from the leaves of Catharanthus roseus and it is remarkably effective in treatment of acute lymphoblastic leukemia, Hodgkin’s disease and non-Hodgkin’s disease, which was approved for marketing by the US FDA in 1960 (12). There are many natural anti-tumor active ingredients like this, such as paclitaxel, brucea oil, etc. However, at present, there are relatively few studies on traditional Chinese medicine for GBM. Therefore, this paper mainly reviews the experimental study of some traditional Chinese medicines in glioblastoma, and provides reference for its future treatment or adjuvant therapy.

2. The general principle of TCM in the treatment of GBM

As stated in Huangdi’s Canon of Medicine, if the body owns sufficient vital qi inside, the pathogenic qi can’t invade. The so-called "vital qi" is the body’s resistance to the pathogenic microorganisms and the body’s ability to adjust and adapt. However, "pathogenic qi" refers to various pathogenic factors, including wind, cold, summer-heat, dampness, dryness, heat (fire). Surely, whether the disease occurs is determined by the result of the struggle between the vital qi and the pathogenic qi in the body. If the vital qi is victorious, then it will not happen; however, if the pathogenic qi is successful, then the disease will occur, according to the theory of TCM. Therefore, strengthening vital qi with eliminating pathogenic qi is the general principle of treating diseases.

2.1. The traditional Chinese medicines against glioblastoma with strengthening vital qi

The most traditional Chinese medicines with the function
of strengthening vital qi in the body have the effect of invigorating qi and nourishing blood, nourishing yin and strengthening yang, in order to improve the body's immunity and resistance, expel the pathogen, and achieve the purpose of overcoming diseases and restoring health, as shown in Table 1

2.1.1. Panax Ginseng

Panax Ginseng has the effect of reinforcing vital energy and is known as the king of the herbs in the Orient, which originates in the dried root of the Araliaceae plant Panax ginseng C.A.Mey (Figure 1A) (13,14). It has gained popularity as a tonic, prophylactic and restorative agent for at least 2000 years (13). Red ginseng is a cooked product of ginseng. Its medicinal properties are warmer and better at nourishing (Figure 1B). It is reported that ginseng is contained in many active constituents such as ginsenosides, polysaccharides, alkaloids, glucosides, phenolic acid, and so on (15). Studies on ginseng have focused on ginsenosides, followed by polysaccharides. According to the positioning of sugar moieties at carbon -3 and -6, ginsenosides can be divided into protopanaxadiol (ginsenoside Rb1, Rb2, Rg3, Re, and Rd) and pro-topanaxatriol (ginsenoside Re, Rg1, Rg2, and Rh1) groups; since carbon C-20 position substituted poorly with isobutyl, and it is further divided into 20 (S) and 20 (R) (Figures 1C-1F) (15). Modern pharmacological studies have shown that ginseng has many biological activities including anti-adhesive, anti-tumor, anti-diabetic, anti-age, neuroregulation, immunomodulation, etc. (15). Studies revealed that chronic treatment with 20(s)-Rg3 induced senescence-like growth arrest in U87 glioma cells via AKT activation and p53/p21 signal pathway to induce reactive oxygen species (ROS) generation (16). Also, ginsenoside Rg3 induced growth and induced apoptosis in the U87MG cell lines, the mechanisms were related to the MEK signaling pathway and ROS (17). Additionally, ginsenoside Rd (Gs-Rd) induced apoptosis and inhibited pro-liferation of human glioma U251 cells by up-regulating the expression of caspase-3 and down-regulating the expression of Bcl-2 and hTERT in a dose-time-dependent manner, which may be attributed to inhibition of telomerase activity (18). The combined ginsenoside Rg3 with low-dose metronomic temozolomide displayed additive antiangiogenic effects through arresting the cell cycle and inducing apoptosis in rat C6 and human umbilical vein endothelial cells (19). Some research demonstrated that ginsenoside Rh2 exerted an anti-tumor effect on human A172 glioma cells via induced cell cycle arrest at G1 phase, which was related to modulating the expression of CDK4/CyclinD complex and Akt (20). Compound K, a particular ginsenoside metabolite, inhibits SDF-1-induced cells migration by down-regulating PKCα and ERK1/2 activation and changes downstream signal transduction of the CXCR4/CXCR12 pathway (21). A newstyle administration has been paid more and more attention by people because of its inherent advantages, such as crossing the blood-brain barrier and sustained release. Angiopep-2 functionalized ginsenoside-Rg3 loaded nanoparticles (ANG-Rg3-NP) inhibited the proliferation of C6 glioma cells in a concentration-dependent manner and easily crossed the blood-brain barrier (22). What's more, the synergistic effect of ginsenoside-Rh2 lipid nanoparticles and borneol inhibited the proliferation of C6 glioma cells more effectively (23).

2.1.2. Licorice

Licorice (gancao in Chinese), is the dried root and rhizome of the Glycyrrhiza uralensis Fich, or Glycyrrhiza Bat, or Glycyrrhiza glabra L (Figures 1G and 1H). It was first recorded in Shennong's Herbal Classic (Shennong Bencao Jing), the oldest Chinese pharmacopoeia, with functions of tonifying the spleen, invigorating qi, dispelling phlegm, relieving coughing, clearing heat, detoxifying, and mediating various medi-cines. Licorice is widely used in clinical prescriptions of traditional Chinese medicine, even "nine out of ten prescriptions contain licorice, which is called "national elder" in China. Up to now, more than 300 flavonoids, more than 20 triterpenoids, polysacchar-ides, and alkaloids have been isolated from it (24). Modern pharmacological studies have shown that licorice possesses multiple biological activities such as antitumor, antiviral, anti-inflammatory, antioxidative immunoregulatory, hepatoprotective, nerve protective and other activities (25). Licochalcone A (LA) is a natural chalone derived from licorices and its chemical structure is shown in Figure 1(I). It induced mitochondrial dysfunction in glioma stem cells to further activate mitochondrial apoptosis signaling pathways, which led to cell death in vitro (26). Besides, a recent study indicated that LA inhibited U87 gliomas cell growth by concurrently arresting cell cycle in the G0/G1 and G2/M phases (27). Isoliquiritigenin (ISL), a member of the flavonoids (Figure 1J) has been found to inhibit proliferation and induce differentiation of glioma stem cells through the Notch1 signaling pathway (28). ISL attenuated cell proliferation of U87 cells in a time and concentration dependent manner and arrested cell cycle in the S and G2/M phase. Meanwhile, ISL upregulated expression of p21 and p27 proteins, indicating that caspase mediated apoptosis was an important mechanism of ISL against glioma U87 (29). Moreover, ISL attenuated migration and invasion of SHG44 human glioma stem cells by down-regulating expression of MMP-2 and MMP-9 (30).

2.1.3. Lycium barbarum

Lycium barbarum, the mature fruit of Lycium barbarum L., is also known as wolfberry, gogi berry, and gouqizi...
| TCM name | Tilt the Latin name | Main active compounds | Cell lines | Stages of action | Related pathway | Effects and related mechanisms | Ref. |
|----------|---------------------|-----------------------|------------|-----------------|----------------|-------------------------------|-----|
| Panax Ginseng | Ginseng Radix et Rhizoma | 20(s)-Rg3 | U87 | Induced senescence | AKT and p53/p21 | ↑p-Akt; ↑p53; ↑p21; ↑ROS; | 16 |
| ginsenoside Rg3 | U87MG | Induced apoptosis | MEK | Inhibited growth; ↑Bax; ↓Bcl-2; ↑ROS | 17 |
| ginsenoside Rg3 | C6; HUVEC | Antiangiogenesis | - | Arrested cycle at S phase; suppressed proliferation; ↓VEGF; ↓Bcl-2 | 19 |
| ginsenoside Rh2 | U87MG; A172 | Inhibits proliferation; induces cell cycle arrest; | Akt | Arrested cycle at G1 phase; ↓CDK4; ↓CyclinD; ↓Akt; ↓p-Akt | 20 |
| Licorice Glycyrrhiza Radix et Rhizoma | Licochalcone A | glioma stem cells | Induced mitochondrial dysfunction | mitochondrial apoptotic | induced caspase-dependent cell death; Induced mitochondrial fragmentation; reduced the membrane potential; ↓ATP production | 26 |
| Isoliguiritigenin | glioma stem cells | Inhibited proliferation and induced differentiation | Notch1 | ↓Hes1; ↓Notch1; | 28 |
| Isoliguiritigenin | SHG44 human glioma stem cells | Inhibit migration and invasion | - | ↓MMP-2; ↓MMP-9 | 30 |
| Lycium barbarum Lycii Fructus | LBP | rat C6 glioma | Inhibit the growth; prolong the survival; regulate the blood brain barrier | - | ↑CD3+T; ↑CD8+T; ↑TNF-α; ↑CD4 + CD25 + Tr ↑ANXA1; ↓IL-10 | 34-35 |
| LBP | rat C6 gliomas | Inhibit growth, regulate immunity | - | ↓IL-17; ↓Foxp3 mRNA; ↓Treg; ↓Th17/Treg | 36 |
| Angelica sinensis Angelicae Sinensis Radix | AS-C BP | DBTRG-05MG; RG2; G5T/VGH; GBM8401; GBM8901; | Inhibited proliferation, arrested cell cycle in the G0-G1 phase; induced apoptosis | p53-dependent and p53-independent pathways | Inhibited proliferation; arrested cell cycle in the G0-G1 phase; induced apoptosis; ↑P21; ↑P16; ↓p-Rb; ↑P53; ↑P21; ↑Bax; ↓Bcl-2; ↑caspase9; ↑caspase3; ↑Fox; ↓caspase 8 | 40-41 |
| PCH4 | DBTRG-05MG; GBM8401 | Inhibited growth; induced apoptosis; reduced migrate; | JNK signaling pathway | ↑p-JNK; ↑p-ERK; ↑Nur77; | 42 |
| APs | U251 | Inhibited growth; inhibited proliferation; induce apoptosis | (TGF-β) | arrest cell cycle in G0/G1 phase; ↓cyclins D1, B, and E; ↓Bcl-2; ↓Bax; ↓cleaved-caspase-3; ↓E-cadherin | 44 |
Moreover, further studies). More than 50 (31,32 35 31,32 36). The plants of licorice (38 BioScience Trends. 2019; 13(6):476-487. (J) which mechanism may be related to 91). Lycium barbarum polysaccharides (LBPs) accounted for 5.42-8.23% of total dried fruit and were considered for 5.42-8.23% of total dried fruit and were considered the most major ingredients, while measuring the quality and pharmacological activities of lycium barbarum (31,32). It was reported that LBPs have many biological activities, such as antiaging, neuroprotection, immunoregulatory, antioxidant, hepatoprotective, renalprotective, antidiabetic, antitoxic, and antitumor. Recent research demonstrated that LBPs inhibited the growth of tumors and prolonged the survival of rats C6 gliomas in vivo, which mechanism may be related to the regulation of immunity and the blood-brain barrier accompanying CD8+ Tcells entering the brain, exerting antitumor effects (34). This was consistent with the findings of Shan et al. in 2015 (35). In addition, the combination LBPs and temozolomide (TMZ) can better inhibit tumor growth compared to TMZ alone on brain glioma in rats, and this may be connected with regulation and distribution of Th17 and Treg cells (36). In short, the anti-GBM effect of LBPs may be related to immune regulation, but the specific mechanism remains unclear. In addition, there are few studies published in the English literature, and further research is needed.

2.1.4. Angelica sinensis

Angelica sinensis, called danggui in Chinese, is the root of Angelica sinensis (Oliv) Diels (Figures 1M and 1N). It is a Chinese herbal medicine with a history of more than 2000 years and a good medicine for tonifying blood (37). It can be cultivated in many provinces in China, especially in Minxian County, Gansu Province (38). According to ancient Chinese medicine records Angelica sinensis has the functions of tonifying blood and regulating menstruation, promoting blood circulation and relieving pain, moistening intestine and relaxing bowel. It is mainly used to treat various gynecological diseases, including dysmenorrhea, amenorrhea, irregular menstruation, menopause and postpartum blood deficiency (37,38). More than 50 constituents have been isolated from the roots of Angelica sinensis. However, more than 165 constituents have been isolated from the whole plant since the 1970s (38). The chemical constituents of it include volatile oil, organic acids, polysaccharides and flavonoids. According to the current Chinese Pharmacopoeia (2010 edition), Z-ligustilide and ferulic acid have been officially used as marker compounds to characterize the quality of Angelica sinensis (38). In addition, polysaccharides have also attracted widespread attention as one of its main components (39). A series of studies have confirmed that Angelica siensis and its derivatives have anti-glioma effects. AS-C, a chloroform extract from it, treated with glioma cells, showed that it not only inhibited cell proliferation, arrested cell cycle in the G0-G1 phase, induced apoptosis through P53-dependent and independent pathways, but had less toxic side effects compared with the current chemotherapy drugs such as Carmustine (BCNU), Taxol, and Temozolomide (+40). Moreover, further studies confirmed that n-butyldieneephthalide (BP), a major component of Angelica sinensis chloroform extract
(Figure 1O), has the same mechanism of action against glioma as described above (41). In order to study the gene expression of BP-induced glioma cell apoptosis, studies have shown that BP increased the expression of Orphan nuclear receptor Nur77-gene, releasing Nur77 from the nucleus to the cytoplasm, releasing cytochrome C from mitochondria, and activating mitochondria-associated apoptotic pathway (42). In addition, PCH4 is one of the derivatives of BP (Figure 1P), which has four times the anti-tumor effect of BP and induces Nur77-mediated apoptosis via the JNK signaling pathway (43). Z-ligustilide (LIG), an essential oil extract of Angelica sinesis, significantly reduces the migration of Human Glioblastoma T98G Cells (44). Angelica polysaccharides (APs) could inhibit U251 glioma cells proliferation, arrest cell cycle in G0/G1 phase, and promote apoptosis by up-regulating Bax and cleaved-caspase-3 and down-regulating Bcl-2 expression in vitro and in vivo (45).

2.2. The traditional Chinese medicines against glioblastoma with eliminating pathogenic qi

The most traditional Chinese medicines with the function of eliminating pathogenic qi in the body have the effect of clearing heat and removing toxins, activating blood and removing stasis, in order to directly expel the pathogen, promote blood circulation, and achieve the purpose of overcoming diseases and restoring health, as shown in Table 2.

2.2.1. Salvia miltiorrhiza Bunge

Salvia miltiorrhiza Bunge, also known as danshen in Chinese, derived from the dried roots and rhizomes of a salvia species of Lamiaceae family (Figures 2A and 2B). It was first cited in Shen Nong Ben Cao Jing and was classified as top grade goods, with the effect of promoting blood circulation to regulate menstruation, dispelling blood to relieve pain, cooling blood to eliminate carbuncles, and tranquillizing mind (46). So far, there has been broad studies on the chemical constituents and pharmacological activities of it. It was found that Danshen contains more than 200 chemical constituents, which have been isolated and identified (46-48). These chemical constituents were classified into three groups according to their structures, such as lipophilic diterpenoids, hydrophilic phenolic acids and others, and the first two were considered to be the main bioactive constituents of Danshen (47,48). The lipophilic diterpenoids are mainly composed of tanshinones, including tanshinone I, tanshinone IIA, tanshinone IIB, cryptotanshinone, dihydrotanshinone etc. However, hydrophilic phenolic acids mainly included salvianolic acid A-E, rosmarinic acid and so on (49). Numerous studies have demonstrated its bioactivities such as anti-oxidative, anti-inflammation, anti-atherogenesis, anti-thrombosis, anti-hypertension, anti-fibrotic, immunoregulatory, neuroprotective, anti-tumor, etc. Relevant literature has shown that many extracts of Danshen possess antiglioma properties. Dihydrotanshinone (Figure 2C) could effectively inhibit the proliferation of human glioma SHG-44 cells in a dose and time dependent manner and induce apoptosis via activation of caspase-3 and caspase-9 and promoting the release of cytochrome C, which further leads to nuclear condensation and DNA fragmentation (50). Moreover, in vitro Glioblastoma model experiment, dihydrotanshinone could increase the efficacy of temozolomide and reduce side effects (51). In addition, cryptotanshinone (Figure 2D) has been reported to inhibit U87 cells and T78G cells proliferation and arrest in G1/G0 phase via downregulating cell cycle-related proteins cyclinD1 and survivin regulated by the STAT3 signaling pathway (32). Wang et al. demonstrated that tanshinone IIA (Figure2E) suppressed proliferation, induced apoptosis and differentiation in human glioma U87 cells (53). Additionally, Tang et al. also showed that tanshinone IIA inhibited growth and induced apoptosis in rat C6 glioma cells, which was related to the STAT3 signaling pathway (54).

2.2.2. Scutellaria baicalensis

Scutellaria baicalensis (huangqin in Chinese), is the dried root of the perennial herb Lamiaceae family Scutellaria baicalensis Georgi (Figures 2F and 2G). The earliest description of it was recorded in the Shijing of the Western Zhou Dynasty, however, Shennong Herbal Classic, written in the Han Dynasty, first recorded its medicinal application (55). In Chinese herbology, it exhibits functions of clearing heat, drying dampness, purging fire and detoxifying, hemostasis, and preventing miscarriage. It has been mainly used in the treatment of jaundice, dysentery, pyrexia, diarrhea, carbuncles, and infections of the respiratory and gastrointestinal tracts (56,57). So far, more than 295 compounds have been isolated from it (58). Among them, flavonoids and their glycosides including baicalin, baicalein, wogonin, wogosides, oroxylin A, are the major compounds with anti-tumor, anti-oxidant, anti-inflammatory, anti-microbial, neuroprotective and other pharmacological activities (58,59). Some studies have shown that Scutellaria baicalensis and its extracts have an anti-glioma effect, which brings hope for the treatment of glioma in the future. Research by Zhang Li et al. showed that Wogonoside (Figure 2H) induced autophagy and promoted apoptosis on different glioma cell lines, the mechanisms of apoptosis were attributed to activation of the p38 MAPK signaling pathway, inhibition of the PI3K/PI3K/AKT/mTOR/p70S6K signaling pathway and production of ROS (60). Wogonin (Figure 2I) effectively inhibited cell growth, induced cell cycle arrest at the G0/G1 phase and induced cell differentiation into mature
## Table 2. Experiments and corresponding mechanisms of some TCM with eliminating pathogenic qi acting on anti-GBM

| TCM name                  | Tilt the Latin name                              | Main active compounds | Cell lines | Stages of action                                      | Related pathway                                                                 | Effects and related mechanisms                                                                 | Ref. |
|---------------------------|--------------------------------------------------|-----------------------|------------|-------------------------------------------------------|--------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|------|
| Salvia miltiorrhiza       | Salviae Miltiorrhizae Radix et Rhizoma            | Dihydrtanshinone      | U87MG; T98G | Inhibited proliferation; induced apoptosis; augmented TMZ efficacy | STAT3                                                                            | ↓proliferation; Induced DNA fragmentation; ↑nuclear condensation; ↑Caspase3; ↑caspase9; ↑cytochrome c; | 50,51|
| Bunge                     |                                                  | cryptotanshinone      | U87; T78G  | Suppress proliferation                                |                                                                                  | ↑proliferation; Arrested cell cycle in G1/G0 phase; ↑cyclin D1; ↑survivin; ↑p-STAT3 Tyr398; attenuated STAT3 nuclear translocation | 52, 53|
| Tanshione IIA             |                                                  |                       | U87        | Inhibited proliferation; induced apoptosis; induced differentiation |                                                                                  | ↑proliferation; Arrested cell cycle in G1/G0 phase; ↑ADPRTL1 mRNA; ↑CYP1A1; ↑GAP; ↑jasmin | 54   |
| Scutellaria baikalensis   | Scutellariae Radix                               | Wogonoside            | U251MG; SHG44; A172; U87MG | Induced autophagy; promoted apoptosis                  | P38 MAPK; PI3K/akt/mTOR/p70S6K;                                                   | Inhibited viability; induced mitochondrial apoptosis; ↑Bcl-2; ↑Bax; ↑cytochrome c; induced autophagy; ↑Beclin 1; ↑LC3-II; ↑p-p38; ↑p-AKT; ↑p-mTOR; ↑p-p70S6K; ↑p-JNK; ↑ROS | 55   |
| Scutellariae baikalensis  |                                                  | wogonin               | C6; U251   | Inhibited proliferation; induced apoptosis; induced differentiation | GSK-3β/β-catenin                                                               | ↓proliferation; Arrested cell cycle in G1/G0 phase; ↑ADPRTL1 mRNA; ↑CYP1A1; ↑GAP; ↑jasmin | 56, 57|
| Scutellaria baikalensis   |                                                  | baicalein             | U87; U251  | Inhibited migration and invasion                      | P38                                                                             | ↓proliferation; ↑migration; ↓invasion; ↓MMP-2; ↓MMP-9; ↑TIMP-1; ↑TIMP-2; ↑p-p38 | 58, 59|
| Coptis Rhizoma            | Coptidis Rhizoma                                 | berberine             | U87; U251  | Changed morphology; inhibited proliferation; interated migration | STAT3                                                                            | ↓proliferation; changed morphology; ↓migration; induced G2/M arrest; ↓apoptosis; ↑Total caspase3; ↑cleaved caspase 3; ↓HDAC3; ↑p-STAT3 | 60   |
| Radix                     |                                                  | berberine             | T98G; U87; | Inhibited angiogenesis                                | VEGF2/ERK                                                                        | ↓apoptosis; ↑angiogenesis; ↑CD31; ↑p-VEGF2; ↑p-ERK; ↑p-p38                           | 61   |
| Coptis chinensis granules |                                                  | berberine             | U87; U251  | Inhibited autophagy; induced apoptosis; induced migration and invasion | EGFR-MEK-ERK/AMPK/mTOR/ULK1                                                         | ↓proliferation; ↓ROS; ↑Ca2+; ↑ER stress; mitochondrial dysfunction; ↓migration; ↓invasion; ↑p-ERK; ↑p-eIF2α; ↑p-AMP; ↑p-MKP; ↑p-p70S6K; ↑p-p-JNK; ↑p-mTOR | 62   |
| Coptis chinensis granules |                                                  | celastrol             | U251; U87; | Inhibited proliferation; induced apoptosis; induced autophagy | ROS/JNK; AKT/mTOR                                                                | ↓proliferation; ↑ROS; ↓ER stress; mitochondrial dysfunction; ↓migration; ↓invasion; ↑p-ERK; ↑p-eIF2α; ↑p-AMP; ↑p-MKP; ↑p-p70S6K; ↑p-p-JNK; ↑p-mTOR | 63   |
| Coptis chinensis granules |                                                  | triptolide            | U251; U87; | induced apoptosis; induced migration and invasion     | P53-independent                                                                  | ↓proliferation; ↓ROS; ↑Ca2+; ↑ER stress; mitochondrial dysfunction; ↓migration; ↓invasion; ↑p-ERK; ↑p-eIF2α; ↑p-AMP; ↑p-MKP; ↑p-p70S6K; ↑p-p-JNK; ↑p-mTOR | 64   |
| Sophora flavescens        | Sophorae Flavescentis Radix                     | matrine               | U251; U87  | induced apoptosis; induced migration and invasion     | P38 MAPK and AKT                                                                  | ↓proliferation; ↓migration; ↓N-cadherin; ↓EMT; ↑E-cadherin; ↑p-p88; ↑p-AKT | 65   |
| Sophora flavescens        |                                                  | matrine               | U251; U87  | induced apoptosis; induced migration and invasion     | P38 MAPK and AKT                                                                  | ↓proliferation; ↓migration; ↓N-cadherin; ↓EMT; ↑E-cadherin; ↑p-p88; ↑p-AKT | 66   |
| Sophora flavescens        |                                                  | oxymatrine            | U251       | Inhibited proliferation; induced apoptosis            | EGFR/P13K/AKT and mTOR and STAT3                                                 | ↓proliferation; ↓migration; ↓N-cadherin; ↓EMT; ↑E-cadherin; ↑p-p88; ↑p-AKT | 67, 68|
| Sophora flavescens        |                                                  |                      |            |                                                       |                                                                                  | ↓proliferation; ↓migration; ↓N-cadherin; ↓EMT; ↑E-cadherin; ↑p-p88; ↑p-AKT | 69   |
| Sophora flavescens        |                                                  |                      |            |                                                       |                                                                                  | ↓proliferation; ↓migration; ↓N-cadherin; ↓EMT; ↑E-cadherin; ↑p-p88; ↑p-AKT | 70   |
| Sophora flavescens        |                                                  |                      |            |                                                       |                                                                                  | ↓proliferation; ↓migration; ↓N-cadherin; ↓EMT; ↑E-cadherin; ↑p-p88; ↑p-AKT | 71   |
astrocytes, which may be related to the inhibition of the GSK-3β/β-catenin signaling pathway in C6 and U251 cells (61). In addition, wogonin induced growth arrest at the G1 phase, suppressed protein synthesis by activating AMPK to inhibit the mTOR pathway, induced apoptosis by activating the AMPK and p53 signaling pathways in human glioblastoma cells (62). Furthermore, it has also been reported that wogonin induced apoptosis via ROS generation and ER stress activation in U251 and U87 Human Glioma Cells (63). Baicalin (Figure 2J) reduced cell mobility, inhibited invasion and metastasis of U87MG and U251MG cell lines in vitro via downregulating MMP-2 and MMP-9 expression and upregulating TIMP-1 and TIMP-2 expression through directly inhibiting the p38 signaling pathway (64).

2.2.3. Coptis Rhizoma

Coptis Rhizoma (CR), known as huanglian in China, is the dried rhizome of the family Ranunculaceae, which included Coptis chinensis Franch. (Weilian in Chinese), Coptis deltoidea C.Y. Cheng et Hsiao (Yalian in Chinese), or Coptis teeta Wall. (Yunlian in Chinese) (Figures 2K and 2L) (65,66). CR was also first mentioned in the Shen Nong Ben Cao Jing and was recorded with the effect of clearing heat, eliminating dampness, purging fire and detoxification (66). It is usually used to treat diarrhea, vomiting, abdominal distention, jaundice, high fever and coma, toothache, diabetes and eczema (66). Modern studies have confirmed that CR has multiple pharmacological spectrums, such as antibacterial, antiviral, anti-inflammatory, antihepatic steatosis, anti-atherosclerosis, antimycocardial ischaemia/reperfusion injury, antidiabetic, antihypertention, antihyperlipidemia, antiarrhythmia, antioxidation and antitumour effects (66). These pharmacological actions are closely related to its structure and active ingredients. So far, more than 100 components have been identified and separated from it. Among these, alkaloids are considered as the main bioactive ingredients, including berberine, palmatine, coptisine, epiberberine, jatrorrhizine and columarine (66,67).

Many studies have shown that Coptis Rhizoma and its extract have obvious anti-glioma effects. In vivo and in vitro experiments have shown that coptis chinensis granules inhibited the proliferation of glioma cells, arrested cell cycle in G2/M phase and induced apoptosis via the down-regulation of photosynthesis of STAT3 by reducing HDAC3 (68). Berberine (Figure 2M) not only significantly inhibited inflammatory cytokine Caspase-1 activation via ERK1/2 signaling and subsequently decreased production of IL-1β and IL-18 in U251 and U87 cells, but inhibited the process of EMT through upregulating the protein expression of β-catenin, α-catenin, and downregulating the protein expression of vimentin, α-SMA, so, it could effectively inhibit glioma cell proliferation, invasion and metastasis (69). Jin reported that berberine exerted the function of anti-angiogenesis in glioblastoma via targeting the VEGFR2/EPK pathway (70). Sun reported that berberine could inhibit mitochondrial aerobic respiration and induce oncosis-like cell death (71). Besides, berberine also was reported to induce autophagy by inhibiting the AMPK/mTOR/ULK1 pathway and induce senescence by the EGFR-MEK-ERK signaling pathway, and induce apoptosis via ER stress, ROS and mitochondrial-dependent pathway in glioblastoma cells (72-74).

2.2.4. Thunder God Vine

www.biosciencetrends.com
Thunder god vine (Leigongteng in Chinese) is the dried root or xylem of the root of the Tripterygium wilfordii hook.f. the family Celastraceae (Figures 2N and 2O). According to the records, Tripterygium wilfordii has the functions of dispelling wind dampness, activating blood circulation, removing swelling and pain, killing insects and detoxifying. So, it has been widely used to treat rheumatoid arthritis, nephrotic syndrome, systemic lupus erythematosus, dermatitis, eczema and so on (75). Recently, people are paying more attention to its role as an anti-tumor agent. More than 300 compounds have been identified from it, and celastrol and triptolide are the most effective bioactive components, its chemical structures are shown in Figures 2P and 2Q (75,76). Previous research has shown that Celastrol inhibits tumor growth and reduces the density of microvessels and inhibits the expression and transcription of VEGF receptors (VEGFR-1 and VEGFR-2) in nude mice human glioma xenografts (77). Recent research confirmed that celastrol inhibited proliferation, arrested cell cycle in G2/M phase, induced apoptosis and triggered autophagy in glioma cells, which was closely related to the activation of ROS/INK signaling and the blockade of the Akt/mTOR signaling pathway (78). Of course, triptolide, another major natural compound of Tripterygium wilfordii, also has anti-glioma effects. Triptolide had been reported to inhibit the proliferation and invasion, and induce apoptosis of glioma cells, and enhance temozolomide-induced apoptosis and potentiate inhibition of NF-κB signaling in glioma initiating cells (79-81).

2.2.5. Sophora flavescens

Sophora flavescens (kushen in Chinese) is the dried root of the Fabaceae family Sophora flavescens Ait., which also was first recorded in Shen Nong Ben Cao Jing (Figures 2R and 2S). It has the effect of clearing heat and dampness, killing insects and diuresis, according to the theory of traditional Chinese medicine. It is mainly used to treat dysentery, jaundice, hematochezia, eczema and other skin diseases as well as gynecopathy such as pruritus and swelling of vulva (82). It is also popular in Japan, Korea, Hawaii and other countries (83). More than 200 compounds were isolated and identified from it, among which alkaloids and flavonoids are its main active ingredients (83). Among these, matrine and oxymatrine chemical structures are as shown in Figure 2T and 2U. They are also the main biologically active ingredients and have a wide range of pharmacological effects such as antiinflammatory, antiviral, antifibrotic, antiallergic, immunoregulatory, antitumor and so on (84,85). A great amount of research has revealed that matrine and oxymatrine have anticancer activity such as lung cancer, breast cancer, liver cancer, gastric cancer, pancreatic cancer and other cancers (84). Assuredly, it also has an anti-glioma effect. Matrine could inhibit invasion and metastasis in human glioma cells via regulating epithelial-to-mesenchymal transition, which may be related to the inhibition of p38 MAPK and AKT signaling (86). Matrine could induce apoptosis and autophagy in U251 cells through down-regulating circRAN-104075 and Bcl-9 expression, which is attributed to regulate the PI3K/AKT and Wnt-β-catenin pathways (87). Oxymatrine also inhibited proliferation and migration, as well as promoted apoptosis in Human Glioblastoma Cells (88). In addition, Wang et al further proved that Oxymatrine inhibited proliferation, arrested the cell cycle at the G0/G1 phase, induced apoptosis via the EGFR/PI3K/Akt/mTOR signaling pathway and STAT3 in U251MG human malignant glioma cells (89).

3. Conclusion

Glioblastoma, as a WHO grade IV glioma, is the most common primary malignant intracranial tumor. At present, conventional treatment (surgery, chemoradiotherapy) can't significantly improve the survival of patients. Hence, it is time to adopt novel personalized treatment programs such as targeted therapy, immunotherapy, gene therapy, traditional Chinese medicine therapy and other ways. Traditional Chinese medicine, as an important part of complementary and alternative medicine, the toxicity and safety of it have received increasing attention, but rational treatment and optimal application may avoid this problem (90). Traditional Chinese medicine play an important role in various diseases, whether used alone or in combination with Western therapy. Its active ingredients and derivatives have made great achievements in the treatment of diseases, such as artemisinin, vincristine, and paclitaxel, PHY906 and so on. This article studied the effects of active ingredients and derivatives about a part of traditional Chinese medicine on anti-glioblastoma, from the two aspects of strengthening vital qi and eliminating pathogenic qi. We find that the active components and derivatives of traditional Chinese medicine have functions of inhibiting proliferation, inducing cell cycle arrest, inhibiting invasion and migration, inducing apoptosis, anti-angiogenesis and improving immunity. However, since the current study is still relatively small, it is necessary to have large samples, and multicenter randomized double-blind controlled trials in the future. In addition, we also found that the same active ingredient can act on different signaling pathways. Hence, this multitarget, multi-level pathway would likely bring new directions for the treatment or adjuvant therapy of glioblastoma in the near future.

Acknowledgements

This study was funded by National Natural Science Foundation of China (No.81503613) and National Natural Science Foundation of China (No. 81603449).
References

1. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16 Suppl 4:i1-63.

2. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131:803-820.

3. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013; 19:764-772.

4. Qazi MA, Vora P, Venugopal C, Sidhu SS, Moffat J, Swanton C, Singh SK. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Ann Oncol. 2017; 28:1448-1456.

5. Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2016; 13:561-574.

6. Wang Q, Hu B, Hu X, et al. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell. 2017; 32:42-56.e46.

7. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRα, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17:98-110.

8. Taylor OG, Brzozowski JS, Skelding KA. Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets. Front Oncol. 2019; 9:963.

9. Davis ME. Glioblastoma: Overview of Disease and Treatment. Clin J Oncol Nurs. 2016; 20 Suppl:S2-8.

10. The Lancet O. Rethinking traditional Chinese medicines for cancer. Lancet Oncol. 2015; 16:1514-1515.

11. Ling CQ, Yue XQ, Ling C. Three advantages of using traditional Chinese medicine to prevent and treat tumor. J Integr Med. 2014; 124:331-335.

12. Silverman JA, Deitcher SR. Marqibo® (vincristine sulfate) for the treatment of refractory adult acute lymphoblastic leukemia. Semin Oncol. 2012; 39 Suppl 6:5-10.

13. Xiang YZ, Shang HC, Gao XM, Zhang BL. A comparison of the ancient use of ginseng in traditional Chinese medicine with modern pharmacological experiments and clinical trials. Phytother Res. 2008; 22:851-858.

14. Qi F, Zhao L, Zhou A, Zhang B, Li A, Wang Z, Han J. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends. 2015; 9:16-34.

15. Ru W, Wang D, Xu Y, He X, Sun YE, Qian L, Zhou X, Qin Y. Chemical constituents and bioactivities of Panax ginseng (C. A. Mey.). Drug Discov Ther. 2015; 9:23-32.

16. Sin S, Kim SY, Kim SS. Chronic treatment with ginsenoside Rg3 induces Akt-dependent senescence in human glioma cells. Int J Oncol. 2012; 415:1669-1674.

17. Choi YJ, Lee HJ, Kang DW, Han IH, Choi BK, Cho WH. Ginsenoside Rg3 induces apoptosis in the U87MG human glioblastoma cell line through the MEK signaling pathway and reactive oxygen species. Oncol Rep. 2013; 303:1362-1370.

18. Gu B, Wang J, Song Y, Wang Q, Wu Q. The inhibitory effects of ginsenoside Rd on the human glioma U251 cells and its underlying mechanisms. J Cell Biochem. 2019; 1203:4444-4450.

19. Sun C, Yu Y, Wang L, Wu B, Xia L, Feng F, Ling Z, Wang S. Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro. J Exp Clin Cancer Res. 2016; 35:32.

20. Li KF, Kang CM, Yin XF, Li HX, Chen ZY, Li Y, Zhang Q, Qiu YR. Ginsenoside Rh2 inhibits human A172 glioma cell proliferation and induces cell cycle arrest status via modulating Akt signaling pathway. Mol Med Rep. 2018; 172:3062-3068.

21. Kim H, Roh HS, Kim JE, Park SD, Park WH, Moon JY. Compound K attenuates stromal cell-derived growth factor 1 (SDF-1)-induced migration of C6 glioma cells. Nutr Res Pract. 2016; 103:239-264.

22. Su X, Zhang D, Zhang H, Zhao K, Hou W. Preparation and Characterization of Angiopep-2 Functionalized Ginsenoside-Rg3 Loaded Nanoparticles and the Effect on C6 Glioma Cells. Pharm Dev Technol. 2019; 1-37.

23. L.Z., J.F., W.L., T.Y., X.H., G.L., L.Y. Preparation and characterization of ginsenoside-Rh2 lipid nanoparticles and synergistic effect with borneol in resisting tumor activity. Zhongguo Zhong Yao Za Zhi. 2016; 4107:1235-1240 (in Chinese).

24. Wang L, Yang R, Yuan B, Liu Y, Liu C. The antiviral and antimicrobial activities of licorice, a widely-used Chinese herb. Acta Pharm Sin B. 2015; 54:310-315.

25. Asl MN, Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res. 2008; 226:709-724.

26. Kuramoto K, Suzuki S, Sakaki H, Takeda H, Sanomachi T, Seino S, Narita Y, Kayama T, Kitanaka C, Okada M. Licochalcone A specifically induces cell death in glioma stem cells via mitochondrial dysfunction. FEBS Open Bio. 2017; 76:835-844.

27. Lu WJ, Wu GJ, Chen RJ, Chang CC, Lien LM, Chiu CC, Tseng MF, Huang LT, Lin KH. Licochalcone A attenuates glioma cell growth in vitro and in vivo through cell cycle arrest. Food Funct. 2018; 9:4500-4507.

28. Lin Y, Sun H, Dang Y, Li Z. Isoliquiritigenin inhibits the proliferation and induces the differentiation of human glioma stem cells. Oncol Rep. 2018; 392:687-694.

29. Zhou GS, Song LJ, Yang B. Isoliquiritigenin inhibits proliferation and induces apoptosis of U87 human glioma cells in vitro. Mol Med Rep. 2013; 72:531-536.

30. Y. D., Y.L., L.J., S.J., S.D., L., Z.Y. Isoliquiritigenin can inhibit migration and invasion of human glioma stem cells by down-regulating matrix metalloproteinases. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2018; 4702:181-186. (in Chinese).

31. Macri A, Carradori S, Casadei MA, Paolicelli P, Petralito S, Ragno R, Cesa S. Lycium barbarum polysaccharides: Extraction, purification, structural characterisation and evidence about hypoglycaemic and hypolipidaemic effects. A review. Food Chem. 2018; 254:377-389.

32. Masci A, Carradori S, Casadei MA, Paolicelli P, Petralito S, Ragno R, Cesa S. Lycium barbarum polysaccharides: Extraction, purification, structural characterisation and evidence about hypoglycaemic and hypolipidaemic effects. A review. Food Chem. 2018; 254:377-389.

33. Xiao X, Ren W, Zhang N, Bing T, Liu X, Zhao Z, Shangguan D. Comparative Study of the Chemical Constituents and Bioactivities of the Extracts from Fruits, Leaves and Root Barks of Lycium barbarum. Molecules. 2017; 226.
BioScience Trends. 2019; 13(6):476-487.

www.biosciencetrends.com

34. JC W, YR Z, Y L, Q W, B Z, HB L, W Z, B S. Lycium barbarum polysaccharide inhibits the growth of rat glioma by regulating the blood-brain barrier. Tumor. 2018; 3802:102-110+151 (in Chinese).

35. TY S, XL P, J D, SH Z, MF W, DZ H, FL L, Z Y, HP Z, GY L. Effect and Its Mechanism of Lycium Barbarum Polysaccharide Combined with Temozolomide on Rat Glioma. Guangdong Medical Journal 2015; 3623:3601-3603 (in Chinese).

36. XF L, JR L, XY L, DC W, MS Z. The effect and mechanisms of combined lyceum bararum polysaccharides with temozolomide on brain glioma in rats . Journal of Guangxi Medical University 2017; 3403:350-354.(in Chinese).

37. Hook IL. Danggui to Angelica sinensis root: are potential benefits to European women lost in translation? A review. J Ethnopharmacol. 2014; 1521:1-13.

38. Wei WL, Zeng R, Gu CM, Qu Y, Huang LF. Angelica sinensis in China-A review of botanical profile, ethnopharmacology, phytochemistry and chemical analysis. J Ethnopharmacol. 2016; 190:116-141.

39. Jin M, Zhao K, Huang Q, Xu C, Shang P. Isolation, structure and bioactivities of the polysaccharides from Angelica sinensis (Oliv.) Diels: a review. Carbohydr Polym. 2012; 893:713-722.

40. Tsai NM, Lin SZ, Lee CC, Chen SP, Su HC, Chang WL, Harn HJ. The antitumor effects of Angelica sinensis on malignant brain tumors in vitro and in vivo. Clin Cancer Res. 2005; 119:3475-3484.

41. Tsai NM, Chen YL, Lee CC, Lin PC, Cheng YL, Chang WL, Lin SZ, Harn HJ. The natural compound n-butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo. J Neurochem. 2006; 99:1251-1262.

42. Lin PC, Chen YL, Chiu SC, Yu YL, Chen SP, Chien MH, Chen KY, Chang WL, Lin SZ, Chiou TW, Harn HJ. Orphan nuclear receptor, Nur-77 was a possible target gene of butylidenephthalide chemistry on glioblastoma multiform brain tumor. J Neurochem. 2008; 1063:1017-1026.

43. Chang LF, Lin PC, Ho Li, Liu PY, Wu WC, Chiang IP, Chang HW, Lin SZ, Harn YC, Harn HJ, Chiou TW. Overexpression of the orphan receptor Nur77 and its translocation induced by PCH4 may inhibit malignant glioma cell growth and induce cell apoptosis. J Surg Oncol. 2011; 103:442-450.

44. Yin J, Wang C, Mody A, Bao L, Hung SH, Svoronos SA, Tseng Y. The Effect of Z-Ligustilide on the Mobility of Human Glioblastoma T9G Cells. PLoS One. 2013; 8:e66598.

45. Zhang WF, Yang Y, Li X, Xu DY, Yan YL, Gao Q, Jia AL, Duan MH. Angelica polysaccharides inhibit the growth and promote the apoptosis of U251 glioma cells in vitro and in vivo. Phytomedicine. 2017; 33:21-27.

46. Xu J, Wei K, Zhang G, Lei L, Yang D, Wang W, Han Q, Xia Y, Bi Y, Yang M, Li M. Ethnopharmacology, phytochemistry, and pharmacology of Chinese Saavia species: A review. J Ethnopharmacol. 2018; 225:18-30.

47. Pang H, Wu L, Tang Y, Zhou G, Qu C, Duan JA. Chemical analysis of the herbal medicine salviae miltiorrhiza Radix et Rhizoma (Danshen). Molecules. 2016; 211:51.

48. XD ME, Cao YF, Che YY, Li J, Shang ZP, Zhao WJ, Qiao YJ, Zhang YJ. Danshen: a phytochemical and pharmacological overview. Chin J Nat Med. 2019; 171:59-80.

49. Shi M, Huang F, Deng C, Wang Y, Kai G. Bioactivities, biosynthesis and biotechnological production of phenolic acids in Salvia miltiorrhiza. Crit Rev Food Sci Nutr. 2019; 596:953-964.

50. Cao Y, Huang B, Gao C. Salvia miltiorrhiza extract dihydrotanshinone induces apoptosis and inhibits proliferation of glioma cells. Bosn J Basic Med Sci. 2017; 173:235-240.

51. Kumar V, Radin D, Leonard D. Probing the oncolytic and chemosensitizing effects of dihydrotanshinone in an in vitro Glioblastoma Model. Anticancer Res. 2017; 3711:6025-6030.

52. Lu L, Li C, Li D, Wang Y, Zhou C, Shao W, Peng J, You Y, Zhang X, Shen X. Cryptotanshinone inhibits human glioma cell proliferation by suppressing STAT3 signaling. Mol Cell Biochem. 2013; 3811-2:273-282.

53. Wang J, Wang X, Jiang S, Yuan S, Lin P, Zhang J, Lu Y, Wang Q, Xiong Z, Wu Y, Ren J, Yang H. Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells. J Neurooncol. 2007; 821:11-21.

54. Tang C, Xue HL, Huang HB, Wang XG. Tanshinnone IIA inhibits constitutive STAT3 activation, suppresses proliferation, and induces apoptosis in rat C6 glioma cells. Neurosci Lett. 2010; 470:126-129.

55. Zhao T, Tang H, Xie L, Zheng Y, Ma Z, Sun Q, Li X. Scutellaria baicalensis Georgii. (Lamiaceae): a review of its traditional uses, botany, phytochemistry, pharmacology and toxicity. J Pharm Pharmacol. 2019; 719:1353-1369.

56. Cheng CS, Chen J, Tan HY, Wang N, Chen Z, Feng Y. Scutellaria baicalensis and Cancer Treatment: Recent Progress and Perspectives in Biomedical and Clinical Studies. Am J Chin Med. 2018; 461:25-54.

57. Li X, Lee YJ, Kim HY, Tan R, Park MC, Kang DG, Lee HS. Beneficial Effects of Scutellaria baicalensis on Penile Erection in Streptozotocin-Induced Diabetic Rats. Am J Chin Med. 2016; 442:305-320.

58. Shang X, He X, He X, Li M, Zhang R, Fan P, Zhang Q, Jia Z. The genus Scutellaria an ethnopharmacological and phytochemical review. J Ethnopharmacol. 2010; 1282:279-313.

59. Wang ZL, Wang S, Kuang Y, Hu ZM, Qiao X, Ye M. A comprehensive review on phytochemistry, pharmacology, and flavonoid biosynthesis of Scutellaria baicalensis. Pharm Biol. 2018; 56:465-484.

60. Zhang L, Wang H, Cong Z, Xu J, Zhu J, Ji X, Ding K. Wogonoside induces autophagy-related apoptosis in human glioblastoma cells. Oncol Rep. 2014; 323:1179-1187.

61. Wang Y, Zhang Y, Qian C, Cai M, Li Y, Li Z, You Q, Wang Q, Hu R, Guo Q, GSK3beta/beta-catenin signaling is correlated with the differentiation of glioma cells induced by wogonin. Toxicol Lett. 2013; 2222:212-223.

62. Lee DH, Lee TH, Jung CH, Kim YH, Lee HS. Beneficial Effects of Scutellaria baicalensis on Penile Erection in Streptozotocin-Induced Diabetic Rats. Am J Chin Med. 2016; 442:305-320.

63. Pak C, Yeh WL, Huang SM, Tan TW, Lu DY. Wogonin induces apoptosis by activating the AMPK and p53 signaling pathways in human glioblastoma cells. Cell Signal. 2012; 2411:2216-2225.

64. Tsai CF, Yeh WL, Huang SM, Tan TW, Lu DY. Wogonin induces reactive oxygen species production and cell apoptosis in human glioma cancer cells. Int J Mol Sci. 2012; 138:9877-9892.
Li Z. Baicalein reduces the invasion of glioma cells via reducing the activity of p38 signaling pathway. PLoS One. 2014; 92:e90318.

65. Tan HL, Chan KG, Puspainah P, Duangjai A, Saokaw S, Mehmoon Khan T, Lee LH, Goh BH. Rhizoma Coptidis: A Potential Cardiovascular Protective Agent. Front Pharmacol. 2016; 7:362.

66. Wang J, Wang L, Lou GH, Zeng HR, Hu J, Huang QW, Peng W, Yang XB. Coptidis Rhizoma: a comprehensive review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. Pharm Biol. 2019; 571:193-225.

67. Meng FC, Wu ZF, Yin QZ, Lin LG, Wang R, Zhang QW. Coptidis rhizoma and its main bioactive components: recent advances in chemical investigation, quality evaluation and pharmacological activity. Chin Med. 2018; 13:13.

68. Li J, Ni L, Li B, Wang M, Ding Z, Xiong C, Lu X. Coptis Chinensis affects the function of glioma cells through the down-regulation of phosphorylation of STAT3 by reducing HDAC3. BMC Complement Altern Med. 2017; 171:524.

69. Tong L, Xie C, Wei Y, Qiu Q, Liang H, Zhang Y, Xu T, Qian X, Qiu H, Deng H. Antitumor Effects of Berberine on Gliomas via Inactivation of Caspase-1-Mediated IL-1beta and IL-18 Release. Front Oncol. 2019; 9:364.

70. Jin F, Xie T, Huang X, Zhao X. Berberine inhibits angiogenesis in glioblastoma xenografts by targeting the VEGFR2/ERK pathway. Pharm Biol. 2018; 565:665-671.

71. Sun Y, Yu J, Liu X, Zhang C, Cao J, Li G, Liu X, Chen Y, Huang H. Oncosis-like cell death is induced by berberine through ERK1/2-mediated impairment of mitochondrial aerobic respiration in gliomas. Biomed Pharmacother. 2018; 102:699-710.

72. Eom KS, Kim HJ, So HS, Park R, Kim TY. Berberine-induced apoptosis in human glioblastoma T98G cells is mediated by endoplasmic reticulum stress accompanying reactive oxygen species and mitochondrial dysfunction. Biol Pharm Bull. 2010; 3310:1644-1649.

73. Liu Q, Xu X, Zhao M, Wei Z, Li X, Zhang X, Liu Z, Gong Y, Shao C. Berberine induces senescence of human glioblastoma cells by downregulating the EGFREK/MKK signaling pathway. Mol Cancer Ther. 2015; 142:355-363.

74. Wang J, Qi Q, Feng Z, Zhang X, Huang B, Chen A, Prestegarden L, Li X, Wang J. Berberine induces autophagy in glioblastoma by targeting the AMPK/mTOR/ULK1-pathway. Oncotarget. 2016; 7416:69944-69958.

75. Brinker AM, Ma J, Lipsky PE, Raskin I. Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry. 2007; 686:732-766.

76. Liu Z, Ma L, Zhou GB. The main anticancer bullets of the Chinese medicinal herb, thunder god vine. Molecules. 2011; 166:5283-5297.

77. Huang Y, Zhou Y, Fan Y, Zhou D. Celastrin inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett. 2008; 2641:101-106.

78. Liu X, Zhao P, Wang X, Wang L, Zhu Y, Song Y, Gao W. Celastrin mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells. J Exp Clin Cancer Res. 2019; 381:184.

79. Lin J, Chen LY, Lin ZX, Zhao ML. The effect of triptolide on apoptosis of glioblastoma multiforme (GBM) cells. J Int Med Res. 2007; 355:637-643.

80. Zhang H, Zhu W, Su X, Wu S, Lin Y, Li J, Wang Y, Chen J, Zhou Y, Qiu P, Yan G, Zhao S, Hu J, Zhang J. Triptolide inhibits proliferation and invasion of malignant glioma cells. J Neurooncol. 2012; 1091:53-62.

81. Sai K, Li WY, Chen YS, Wang J, Guan S, Yang QY, Guo CC, Mou YG, Li WP, Chen ZP. Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-kappaB signaling in glioma initiating cells. Am J Chin Med. 2014; 422:485-503.

82. Zheng K, Li C, Shan X, Liu H, Fan W, Wang Z. A study on isolation of chemical constituents from Sophora flavescens Ait. and their anti-glioma effects. Afr J Tradit Complement Altern Med. 2014; 111:156-160.

83. He X, Fang J, Huang L, Wang J, Huang X. Sophora flavescens Ait.: Traditional usage, phytochemistry and pharmacology of an important traditional Chinese medicine. J Ethnopharmacol. 2015; 172:10-29.

84. Rashid HU, Xu Y, Muhammad Y, Wang L, Jiang J. Research advances on anticancer activities of matrine and its derivatives: An updated overview. Eur J Med Chem. 2019; 161:205-238.

85. Yong J, Wu X, Lu C. Anticancer Advances of Matrine and Its Derivatives. Curr Pharm Des. 2015; 2125:3673-3680.

86. Wang Z, Wu Y, Wang Y, Jin Y, Ma X, Zhang Y, Ren H. Matrine inhibits the invasive properties of human glioma cells by regulating epithelialmesenchymal transition. Mol Med Rep. 2015; 115:3682-3686.

87. Chi G, Xu D, Zhang B, Yang F. Matrine induces apoptosis and autophagy of glioma cell line U251 by regulation of circRNA-104075/BCL-9. Chem Biol Interact. 2019; 308:198-205.

88. Liu F, Wang B, Wang J, Ling X, Li Q, Meng W, Ma J. Oxymatrine Inhibits Proliferation and Migration While Inducing Apoptosis in Human Glioblastoma Cells. Biomed Res Int. 2016; 2016:1784161.

89. Dai Z, Wang L, Wang X, Zhao B, Bhardwaj SS, Ye J, Yin Z, Zhang J, Zhao S. Oxymatrine induces cell cycle arrest and apoptosis and suppresses the invasion of human glioblastoma cells through the EGF/PI3K/Akt/mTOR signaling pathway and STAT3. Oncol Rep. 2018; 402:867-876.

90. Cai P, Qiu H, Qi F, Zhang X. The toxicity and safety of traditional Chinese medicines: Please treat with rationality. Biosci Trends. 2019; 135:367-373.

91. Zhu YL, Li B, Zhou B. New Atlas of Chinese Herbal Medicine. China Beijing, Chemical Industry Press, 2016; pp. 64-65, p. 545, p. 574, p. 622 (in Chinese).

92. Qu TB. New Chinese herbal medicine illustrated book. China Jiangxi, Jiangxi Science and Technology Press, 2016; pp. 64-65, p. 454, p. 574, p. 622 (in Chinese).